Literature DB >> 15175148

Ocular allergy treatment comparisons: azelastine and olopatadine.

Leonard Bielory1, Praveen Buddiga, Stephen Bigelson.   

Abstract

Azelastine hydrochloride 0.05% and olopatadine hydrochloride 0.1% are topical ocular allergy treatments that have demonstrated multiple pharmacologic actions, including antihistamine, mast cell stabilization, and inhibition of proinflammatory mediators. In this article, the mechanisms of action, efficacy, and tolerability of these two agents on ocular signs and symptoms are examined. By studying the various target sites of drug action, an enhanced clinical response algorithm of these topical ocular agents can be implemented to maximize the response for patients suffering from ocular allergy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175148     DOI: 10.1007/s11882-004-0078-1

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  39 in total

Review 1.  Conjunctival allergen challenge: models in the investigation of ocular allergy.

Authors:  Mark B Abelson; Oliver Loeffler
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

Review 2.  Mast cell heterogeneity.

Authors:  A M Irani; L B Schwartz
Journal:  Clin Exp Allergy       Date:  1989-03       Impact factor: 5.018

3.  Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.

Authors:  D L Spangler; G Bensch; G J Berdy
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 4.  CC chemokines in allergic inflammation.

Authors:  M Baggiolini; C A Dahinden
Journal:  Immunol Today       Date:  1994-03

5.  A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.

Authors:  M N Artal; J D Luna; M Discepola
Journal:  Acta Ophthalmol Scand Suppl       Date:  2000

6.  Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.

Authors:  Giorgio Ciprandi; Cristina Cosentino; Manlio Milanese; Maria Angela Tosca
Journal:  Ann Allergy Asthma Immunol       Date:  2003-04       Impact factor: 6.347

7.  Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.

Authors:  Cullen T Vogelson; Mark B Abelson; Terri Pasquine; Donna M Stephens; Daniel A Gamache; Robert D Gross; Stella M Robertson; John M Yanni
Journal:  Allergy Asthma Proc       Date:  2004 Jan-Feb       Impact factor: 2.587

8.  Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study.

Authors:  C Giede-Tuch; M Westhoff; A Zarth
Journal:  Allergy       Date:  1998-09       Impact factor: 13.146

Review 9.  Role of antihistamines in ocular allergy.

Authors:  Leonard Bielory
Journal:  Am J Med       Date:  2002-12-16       Impact factor: 4.965

10.  Interactions of olopatadine and selected antihistamines with model and natural membranes.

Authors:  Howard L Brockman; Maureen M Momsen; Joshua R Knudtson; Steven T Miller; Gustav Graff; John M Yanni
Journal:  Ocul Immunol Inflamm       Date:  2003-12       Impact factor: 3.070

View more
  1 in total

1.  Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis.

Authors:  Patricia B Williams; Elizabeth Crandall; John D Sheppard
Journal:  Clin Ophthalmol       Date:  2010-09-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.